MPCi

Molecular Precision (MPCi) is a precision medicine biotechnology company focused on the discovery and development of first-in-class small molecule inhibitors targeting the translational control of protein synthesis. The company's proprietary platform identifies novel targets within the MNK1/2 and eIF4E pathways, which are essential for the translation of mRNAs that drive cancer growth, metastasis, and immune evasion. MPCi's lead program, a selective MNK1/2 inhibitor (LY3381916), was developed in a global strategic collaboration with Eli Lilly and has been evaluated in Phase 1 clinical trials for advanced solid tumors. Beyond oncology, the company explores the potential of its translational control inhibitors in treating fibrotic diseases. Founded by Dr. Robert J. Schneider, MPCi leverages deep expertise in molecular biology to address high-need therapeutic areas through innovative protein synthesis modulation.